drugset / Trial / NCT04897750

Pharmacokinetic Study of Intranasal CT001 in Children 1-17 Years of Age Undergoing Elective Surgical Procedures

NCT04897750

Phase 2 Completed 25 enrolled Cessatech A/S
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective non-randomized, open-label, single dose (and a second dose if needed), PK study in 25 children age 1-17 years. The proposed number of study participants by subset is: 8 paediatric participants 1-2 years; 8 paediatric participants \>2-6 years and 9 paediatric participants \>6-17 years.

Timeline

Start
2021-08-19
Primary completion
2022-05-16
Completion
2022-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.5 mg/kg Intranasal
Subject Sufentanil Other / unclassified 0.5 ug/kg Intranasal

Indications